Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biopharma News
Biosimilar Deals 2025
Biosimilar Deals 2026
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Diversity
Helen Macpherson
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Sally Paterson
Trade Marks
Webinars

GlycoNex/Mitsubishi Gas Chemical File Application for Biosimilar Denosumab in Japan

Nov 8, 2026

On 8 November 2026, GlycoNex announced that a marketing authorisation application for SPD8, biosimilar to Amgen’s Prolia® (denosumab) was submitted to Japan’s Pharmaceuticals and Medical Devices Agency (PDMA).

SPD8 was co-developed by GlycoNex with Mitsubishi Gas Chemical.  GlycoNex retains sales, distribution and commercialisation rights to SPD8 in all markets outside Japan and is actively seeking commercialisation partners in these markets.

The submission of the application follows GlycoNex’s June 2026 announcement that SPD8 met the primary endpoint in a Phase 3 osteoporosis study conducted in Japan, demonstrating therapeutic equivalence to Prolia®.

According to GlycoNex, SPD8 could receive regulatory approval in Japan at the end of 2027.  GlycoNex is also preparing for a regulatory submission for SPD8 in Taiwan.

There is one approved denosumab biosimilar in Japan to date, Alvotech/Fuji Pharma’s AVT03 (DENOSUMAB BS 120 mg/1.4 mL in a vial for subcutaneous injection; September 2025), biosimilar to Daiichi Sankyo’s Ranmark® (marketed in other countries as Amgen’s Xgeva®).  On 30 October 2026, China-headquartered Boan Biotech announced that it has licensed BA6101 (denosumab), biosimilar to Amgen’s Prolia®, to an undisclosed partner for Japan.